Poll: Do You Agree with the FDA's Decision to Pull Avastin?

Article

This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.

Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.